|国家预印本平台
首页|Impact of azithromycin mass drug administration on the antibiotic-resistant gut microbiome: a randomized, controlled trial

Impact of azithromycin mass drug administration on the antibiotic-resistant gut microbiome: a randomized, controlled trial

Impact of azithromycin mass drug administration on the antibiotic-resistant gut microbiome: a randomized, controlled trial

来源:medRxiv_logomedRxiv
英文摘要

Abstract BackgroundMass drug administration (MDA) with azithromycin is the primary strategy for global trachoma control efforts. Numerous studies have reported secondary effects of MDA with azithromycin, including reductions in childhood mortality, diarrhoeal disease and malaria. Most recently, the MORDOR clinical trial demonstrated that MDA led to an overall reduction in all-cause childhood mortality in targeted communities. There is however concern about the potential of increased antimicrobial resistance in treated communities. MethodsThis study evaluated the impact of azithromycin MDA on the prevalence of gastrointestinal carriage of macrolide-resistant bacteria in communities within the MORDOR Malawi study, additionally profiling changes in the gut microbiome after treatment. For faecal metagenomics, 60 children were sampled prior to treatment and 122 children after four rounds of MDA, half receiving azithromycin and half placebo. FindingsThe proportion of bacteria carrying macrolide resistance increased after azithromycin treatment; the effect was enhanced in children treated within six months of sampling. Diversity and global community structure of the gut was minimally impacted by treatment, however abundance of several species was altered by treatment. Notably, the putative human enteropathogen Escherichia albertii was more abundant after treatment. InterpretationThe impacts of MDA with azithromycin, including increased carriage of macrolide-resistant bacteria, were enhanced in children treated more recently, suggesting effects may be transient. Increased abundance of enteropathogenic Escherichia species after treatment requires further, higher resolution investigation. Future studies should focus on the number of treatments and administration schedule to ensure clinical benefits continue to outweigh costs in antimicrobial resistance carriage. FundingBill and Melinda Gates Foundation

Stabler Richard、Burr Sarah、Pickering Harry、Bailey Robin L.、Kalua Khumbo、Holland Martin J.、Hart John D.、Maleta Ken

London School of Hygiene and Tropical MedicineLondon School of Hygiene and Tropical Medicine||College of Medicine, University of MalawiLondon School of Hygiene and Tropical MedicineLondon School of Hygiene and Tropical MedicineCollege of Medicine, University of Malawi||Blantyre Institute for Community OutreachLondon School of Hygiene and Tropical MedicineLondon School of Hygiene and Tropical MedicineCollege of Medicine, University of Malawi

10.1101/2021.03.02.20215632

医药卫生理论医学研究方法微生物学

Stabler Richard,Burr Sarah,Pickering Harry,Bailey Robin L.,Kalua Khumbo,Holland Martin J.,Hart John D.,Maleta Ken.Impact of azithromycin mass drug administration on the antibiotic-resistant gut microbiome: a randomized, controlled trial[EB/OL].(2025-03-28)[2025-05-25].https://www.medrxiv.org/content/10.1101/2021.03.02.20215632.点此复制

评论